 | • レポートコード：MRC2203A762 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、121ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の食欲抑制剤市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、投与経路別（皮下、経口）分析、流通チャネル別（オンライン薬局、小売薬局、病院薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の食欲抑制剤市場規模：投与経路別（皮下、経口） ・世界の食欲抑制剤市場規模：流通チャネル別（オンライン薬局、小売薬局、病院薬局） ・世界の食欲抑制剤市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Novo Nordisk Inc.、Lannett Co. Inc.、Currax Pharmaceuticals LLC、...） ・市場機会・将来の傾向 |
The anorexiants market studied is anticipated to register a CAGR of 3.9% during the forecast period. The major factors attributing to the growth of the market are a rise in the sedentary lifestyle, physical inactivity, and poor dietary habits resultant weight gain. According to the World Health Organization report, in 2017, about 650 million adults and 41 million children aged under 5 years were obese worldwide. Also, the report states that the obesity rate is expected to grow rapidly during the forecast period. Thus, a steep rise in global healthcare expenditure to control other health complications and obesity-related diseases is expected to drive the market.
Key Market Trends
Oral Anorexiants Segment is Expected to Hold the Major Market Share in the Anorexiants Market
Oral Anorexiants dominated the market in past few years, and it is expected to do so over the forecast period. The higher demand for these products can be due to the increased preference of the patients owing to their non-invasive treatment. Also, their easier administration without the need for skilled healthcare professionals increased the adoption rate among the patients and physicians. Furthermore, higher availability of products in tablets and capsules, as well as increased awareness by key players are expected to lead to the growth of the segment.
North America Dominates the Market and Expected to do Same in the Forecast Period.
North America has been the primary market for anorexiants market owing to the rise in the number of complications associated with obesity in the region. Major chronic diseases prevailing in the region include diabetes, coronary heart disease, and certain types of cancer.
According to the factsheet published by the Centers for Disease Control and Prevention (CDC), the prevalence of obesity in 2016 was 39.8%, affecting about 93.3 million US adults which increased to 41.2 % in 2017. Also, as per the Organization for Economic Co-operation and Development report in 2020, the United States is estimated to spend the highest Health Expenditure on Obesity and Related Conditions across the globe during 2020-2050.
Increasing obesity cases in the region can be due to a sedentary lifestyle and unhealthy dietary habits. Furthermore, overweight gain affects an individual’s psychological, behavioral, and psychiatric characteristics. Additionally, the presence of key players, a huge target population with disposable income in the United States is anticipated to drive the market growth over the forecast period.
Competitive Landscape
The Anorexiants Market is moderately competitive and consists of several major players. Few of the major players are implementing various strategies like increased investments in R&D and mergers & acquisitions. For instance, in September 2019, Currax Pharmaceuticals LLC, acquired Nalpropion Pharmaceuticals, a biopharmaceutical company focused on the treatment of weight loss. With the acquisition deal, Currax has owned the world-wide rights to Contrave, the number one prescription weight-loss brand medication in the United States and Europe. Strategic alliances such as these are expected to boost the sales globally. Some of the companies currently dominating the market are Novo Nordisk Inc., Lannett Co. Inc., Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, and Pfizer Inc.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles
4.2.2 Rise in Awareness and Disposable Income in Developed Economies
4.3 Market Restraints
4.3.1 Highly Cost of Branded Products in Emerging Countries
4.3.2 Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death
4.3.3 Adoption of Traditional Yoga and Herbal Products
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Route of Administration
5.1.1 Subcutaneous Anorexiants
5.1.2 Oral Anorexiants
5.2 Distribution Channel
5.2.1 Online Pharmacy
5.2.2 Retail Pharmacy
5.2.3 Hospital Pharmacy
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novo Nordisk Inc.
6.1.2 Lannett Co. Inc.
6.1.3 Currax Pharmaceuticals LLC
6.1.4 F. Hoffmann-La Roche AG
6.1.5 Pfizer Inc.
6.1.6 Vivus Inc.
6.1.7 Hi-Tech Pharmaceuticals
6.1.8 KVK Tech Inc.
6.1.9 Elite Pharmaceuticals Inc.
6.1.10 Productos Medix SA de CV
7 MARKET OPPORTUNITIES AND FUTURE TRENDS